colorectal cancer – media

Keytruda scores new EU approval in colorectal cancer

MSD’s immunotherapy Keytruda (pembrolizumab) has been approved in the EU for the first-line treatment of metastatic Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) colorectal cancer. According to MSD, Keytruda is the first checkpoint inhibitor to be approved in the EU to treat MSI-H or dMMR colorectal cancer. The European Commission (EC) approval is based on results from the Phase III KEYNOTE-177 trail. In this study, Keytruda monotherapy significantly reduced the risk of disease progression or death by 40% compared to chemotherapy in this patient population. Treatment with Keytruda also more than doubled median progression-free survival (PFS) compared to chemotherapy – 16.5 months versus 8.2 months. For patients treated with Keytruda, the overall response rate (ORR) was 44%, with a complete response rate of 11% and a partial response rate of 33%. Meanwhile, in the chemotherapy arm, patients demonstrated an ORR of 33%, a complete response rate of 4% and ...
- Source: drugdu
- 292
- January 29, 2021
colorectal cancer
Bristol-Myers Squibb’s Combo Drug gets FDA Approval

Bristol-Myers Squibb’s recent immunotherapy combo won FDA approval for patients with a rare colon cancer. The combinational medicine was formulated between an older medicine named Yervoy and a new cancer-fighter Opdivo. This combo drug focuses on repairing the mismatch gene.
- Source: FiercePharma
- 4,416
- July 13, 2018
Bristol-Myers Squibb cancer colorectal cancer New Approvals
New Use of A.I. Accurately Detected Cancer 86 Percent of the Time

The quest to better detect cancer has made a potentially huge strides. A study out of Yokohama, Japan, has potentially harnessed artificial intelligence to help detect colorectal cancer even before benign tumors become malignant.
- Source: inverse
- 732
- November 1, 2017
Artificial Intelligence colorectal cancer Market Views

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.